Among victims with limb amputation or hemorrhagic shock, survival was improved for recipients versus nonrecipients of prehospital transfusion.
Hemorrhage is a leading cause of traumatic death among both military and civilian victims. To determine if prehospital transfusion improves survival for U.S, military victims, investigators conducted a retrospective cohort study of 502 combat casualties who sustained traumatic injuries in Afghanistan from April 2012 to August 2015. Eligible patients had sustained a traumatic limb amputation at or above the elbow or knee, or had hemorrhagic shock, defined as a heart rate >120 or a systolic blood pressure <90.
Risk for death at 24 hours after MEDEVAC rescue was lower among recipients of prehospital transfusion versus nonrecipients (5% vs. 19%; hazard ratio, 0.26; P=0.02), after adjustment for mechanism of injury, prehospital shock, severity of…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals